| NCT03947255 |
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03947255 |
Recruiting |
Seattle Genetics, Inc. |
2024-12-31 |
| NCT03409432 |
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03409432 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2021-04-30 |
| NCT03278782 |
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin |
https://ClinicalTrials.gov/show/NCT03278782 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT03113500 |
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03113500 |
Recruiting |
City of Hope Medical Center |
2021-01-21 |
| NCT03017820 |
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03017820 |
Recruiting |
Mayo Clinic |
2021-01-15 |
| NCT02978625 |
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
https://ClinicalTrials.gov/show/NCT02978625 |
Recruiting |
National Cancer Institute (NCI) |
2021-06-01 |
| NCT02939014 |
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) |
https://ClinicalTrials.gov/show/NCT02939014 |
Completed |
Takeda |
2018-08-02 |
| NCT02902874 |
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + |
https://ClinicalTrials.gov/show/NCT02902874 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
2018-10-31 |
| NCT02652715 |
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02652715 |
Completed |
Mayo Clinic |
2018-12-21 |
| NCT01028716 |
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01028716 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2024-01-04 |
| NCT02572453 |
Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) |
https://ClinicalTrials.gov/show/NCT02572453 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-10-01 |
| NCT02561273 |
Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT02561273 |
Active, not recruiting |
University of Nebraska |
2020-10-31 |
| NCT03397953 |
Vinorelbine for Recurrent ACLC |
https://ClinicalTrials.gov/show/NCT03397953 |
Recruiting |
Children’s Cancer Group, China |
2018-12-31 |
| NCT02533700 |
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL |
https://ClinicalTrials.gov/show/NCT02533700 |
Active, not recruiting |
Shandong Provincial Hospital |
2019-05-31 |
| NCT02462538 |
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL |
https://ClinicalTrials.gov/show/NCT02462538 |
Active, not recruiting |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2021-06-30 |
| NCT02232516 |
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02232516 |
Recruiting |
Northwestern University |
2022-07-31 |
| NCT02223208 |
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02223208 |
Recruiting |
Fondazione Italiana Linfomi ONLUS |
2021-09-30 |
| NCT02168140 |
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02168140 |
Active, not recruiting |
Wake Forest University Health Sciences |
2019-04-18 |
| NCT03383965 |
CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas |
https://ClinicalTrials.gov/show/NCT03383965 |
Recruiting |
Immune Cell, Inc. |
2020-12-31 |
| NCT01309789 |
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms |
https://ClinicalTrials.gov/show/NCT01309789 |
Completed |
Seattle Genetics, Inc. |
2013-04-30 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01950364 |
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01950364 |
Completed |
Millennium Pharmaceuticals, Inc. |
2014-10-31 |
| NCT01943682 |
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma |
https://ClinicalTrials.gov/show/NCT01943682 |
Completed |
Children’s Hospital Medical Center, Cincinnati |
2019-03-31 |
| NCT01909934 |
Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01909934 |
Recruiting |
Takeda |
2020-09-30 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01787409 |
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency |
https://ClinicalTrials.gov/show/NCT01787409 |
Recruiting |
Mayo Clinic |
2020-11-30 |
| NCT01777152 |
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01777152 |
Active, not recruiting |
Seattle Genetics, Inc. |
2018-08-15 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01719835 |
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study |
https://ClinicalTrials.gov/show/NCT01719835 |
Active, not recruiting |
Royal Marsden NHS Foundation Trust |
2016-11-30 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01657331 |
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) |
https://ClinicalTrials.gov/show/NCT01657331 |
Active, not recruiting |
Columbia University |
2019-12-31 |
| NCT01606878 |
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01606878 |
Completed |
Children’s Oncology Group |
2018-12-31 |
| NCT01590732 |
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01590732 |
Completed |
M.D. Anderson Cancer Center |
2018-05-02 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01578499 |
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) |
https://ClinicalTrials.gov/show/NCT01578499 |
Completed |
Takeda |
2016-05-31 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01524926 |
CREATE: Cross-tumoral Phase 2 With Crizotinib |
https://ClinicalTrials.gov/show/NCT01524926 |
Active, not recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2017-12-06 |
| NCT01492088 |
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01492088 |
Completed |
Takeda |
2016-10-12 |
| NCT01466881 |
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01466881 |
Completed |
National Cancer Institute (NCI) |
2014-12-31 |
| NCT01449461 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) |
https://ClinicalTrials.gov/show/NCT01449461 |
Completed |
Takeda |
2015-11-16 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01336933 |
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01336933 |
Completed |
University of Nebraska |
2016-12-28 |
| NCT01336920 |
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01336920 |
Completed |
University of Nebraska |
2015-04-30 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT04423926 |
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL |
https://ClinicalTrials.gov/show/NCT04423926 |
Recruiting |
The First Affiliated Hospital with Nanjing Medical University |
2022-12-31 |
| NCT04306887 |
A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) |
https://ClinicalTrials.gov/show/NCT04306887 |
Recruiting |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-12-31 |
| NCT04058470 |
Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04058470 |
Recruiting |
Sun Yat-sen University |
2022-12-30 |
| NCT04008394 |
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies |
https://ClinicalTrials.gov/show/NCT04008394 |
Recruiting |
Wuhan Union Hospital, China |
2022-07-01 |
| NCT03905135 |
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies |
https://ClinicalTrials.gov/show/NCT03905135 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-03-01 |
| NCT03719898 |
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03719898 |
Recruiting |
Fox Chase Cancer Center |
2020-12-31 |
| NCT03707847 |
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL |
https://ClinicalTrials.gov/show/NCT03707847 |
Recruiting |
Zhengzhou University |
2020-02-01 |
| NCT03703050 |
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) |
https://ClinicalTrials.gov/show/NCT03703050 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
2024-01-31 |
| NCT03602157 |
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL |
https://ClinicalTrials.gov/show/NCT03602157 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2026-09-30 |
| NCT03598998 |
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03598998 |
Recruiting |
City of Hope Medical Center |
2021-04-27 |
| NCT03590574 |
Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03590574 |
Recruiting |
Autolus Limited |
2021-07-31 |
| NCT03505554 |
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma |
https://ClinicalTrials.gov/show/NCT03505554 |
Recruiting |
University of Milano Bicocca |
2019-12-31 |
| NCT03493451 |
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms |
https://ClinicalTrials.gov/show/NCT03493451 |
Active, not recruiting |
BeiGene |
2021-02-28 |
| NCT03443128 |
Vinorelbine for Recurrent ALCL-2017 |
https://ClinicalTrials.gov/show/NCT03443128 |
Recruiting |
Children’s Cancer Group, China |
2024-12-31 |
| NCT01261247 |
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01261247 |
Active, not recruiting |
Mayo Clinic |
2016-05-09 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01198665 |
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01198665 |
Completed |
Samsung Medical Center |
2014-12-31 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01134341 |
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01134341 |
Completed |
Acrotech Biopharma LLC |
2015-08-31 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01129180 |
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01129180 |
Completed |
Ohio State University Comprehensive Cancer Center |
2012-05-31 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT01035463 |
Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy |
https://ClinicalTrials.gov/show/NCT01035463 |
Completed |
University of Nebraska |
2017-07-27 |
| NCT01026415 |
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) |
https://ClinicalTrials.gov/show/NCT01026415 |
Completed |
Seattle Genetics, Inc. |
2012-05-31 |
| NCT01026233 |
Cardiac Safety Study of Brentuximab Vedotin (SGN-35) |
https://ClinicalTrials.gov/show/NCT01026233 |
Completed |
Seattle Genetics, Inc. |
2010-08-31 |
| NCT00994500 |
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
https://ClinicalTrials.gov/show/NCT00994500 |
Completed |
National Cancer Institute (NCI) |
2011-07-31 |
| NCT00947856 |
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study |
https://ClinicalTrials.gov/show/NCT00947856 |
Completed |
Seattle Genetics, Inc. |
2013-03-31 |
| NCT00939770 |
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00939770 |
Completed |
Children’s Oncology Group |
2018-12-31 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00901147 |
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00901147 |
Completed |
Singapore General Hospital |
2014-01-31 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00866047 |
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00866047 |
Completed |
Seattle Genetics, Inc. |
2010-08-31 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT01686165 |
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL |
https://ClinicalTrials.gov/show/NCT01686165 |
Completed |
University of Arizona |
2016-02-09 |
| NCT02568267 |
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) |
https://ClinicalTrials.gov/show/NCT02568267 |
Recruiting |
Hoffmann-La Roche |
2022-12-01 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00720135 |
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00720135 |
Completed |
City of Hope Medical Center |
2014-07-31 |
| NCT00697346 |
Study of MLN8237 in Participants With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00697346 |
Completed |
Takeda |
2016-10-01 |
| NCT00644189 |
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00644189 |
Active, not recruiting |
Massachusetts General Hospital |
2013-12-31 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00606645 |
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00606645 |
Completed |
Xencor, Inc. |
2010-04-30 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00585195 |
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT00585195 |
Active, not recruiting |
Pfizer |
2020-04-30 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00430846 |
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00430846 |
Completed |
Seattle Genetics, Inc. |
2009-07-31 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00343798 |
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00343798 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-07-31 |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00278382 |
Sorafenib in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00278382 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00199082 |
Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt’s Non-Hodgkin’s Lymphoma (NHL) and Other High-grade Lymphoma in Adults |
https://ClinicalTrials.gov/show/NCT00199082 |
Completed |
Johann Wolfgang Goethe University Hospital |
2010-06-30 |
| NCT00131937 |
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00131937 |
Completed |
National Cancer Institute (NCI) |
2011-09-30 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00117988 |
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00117988 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00105001 |
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00105001 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-05-31 |
| NCT00099255 |
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00099255 |
Completed |
Seattle Genetics, Inc. |
2007-02-28 |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00082888 |
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00082888 |
Completed |
National Cancer Institute (NCI) |
2009-05-20 |
| NCT00005080 |
506U78 in Treating Patients With Lymphoma |
https://ClinicalTrials.gov/show/NCT00005080 |
Completed |
National Cancer Institute (NCI) |
2006-01-31 |
| NCT00079755 |
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00079755 |
Completed |
Seattle Genetics, Inc. |
2006-12-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00077155 |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00077155 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00073918 |
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00073918 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-10-02 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00059839 |
Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00059839 |
Completed |
Children’s Oncology Group |
2009-12-31 |
| NCT00058019 |
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00058019 |
Completed |
National Cancer Institute (NCI) |
2010-08-31 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00016094 |
S0108 Bevacizumab in Treating Patients With Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00016094 |
Completed |
National Cancer Institute (NCI) |
2005-08-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00004241 |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
https://ClinicalTrials.gov/show/NCT00004241 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00003970 |
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00003970 |
Completed |
National Cancer Institute (NCI) |
2003-10-31 |
| NCT00003741 |
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00003741 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00001337 |
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00001337 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-03-31 |